Mannkind (MNKD) Notes Payables (2012 - 2025)

Mannkind (MNKD) reported Notes Payables of $36.3 million for Q4 2025, little changed quarter-over-quarter from $36.2 million in Q3 2025.

Mannkind (MNKD) Notes Payables (2012 - 2025) Analysis & Trends

Mannkind (MNKD) has 7 years of Notes Payables data on file, last reported at $36.3 million in Q4 2025.

Notes Payables for Q4 2025 came in at $36.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $36.3 million (changed N/A YoY), and the FY2025 annual result was $36.3 million, changed N/A from the prior year.
Notes Payables held at $36.3 million in Q4 2025 per MNKD's latest filing, from $36.2 million in the prior quarter.
Over five years, Notes Payables peaked at $36.3 million in Q4 2025 and troughed at $36.1 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Mannkind	1.21 Bn	1.08 Bn	82.66 Mn

Download Data